In December 2024, the FDA granted accelerated approval to BIZENGRI (Merus) for adult patients with advanced, unresectable, or ...

Lung cancer screening guidelines do not exist for individuals who never smoked, but data presented at International ...

The FANSS shows a 1.3% lung cancer detection rate among 1000 Asian women with no smoking history, which is comparable to ...

A team led by Christian Baumgartner of the Institute of Health Care Engineering at Graz University of Technology (TU Graz) ...

The study showed treatment potential for lung adenocarcinoma—a type of non-small cell lung cancer—in particular. This is the most common type of lung cancer seen in the U.S., accounting for 45 percent ...

Central tumour location linked to worse survival in lung cancer, suggesting need for closer post-operation monitoring.

Early trial results report progression-free survival and response rates for ateganosine, spevatamig, Annamycin and pumitamig; ...

Bizengri received accelerated approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, showing ORRs of 33% and 40%, respectively, with varying DORs. Imfinzi significantly improved ...

Montefiore Einstein's Comprehensive Cancer Center's (MECCC) lung cancer team has been nationally recognized by the ...